Paper Details

  1. Home
  2. Paper Details

Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.

Author: AmsterdamJay D, BodkinJ Alexander

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Transdermal selegiline is an effective and well-tolerated treatment for adult outpatients with major depression. The treatment was effective as early as week 1 and no typical side effects of monoamine oxidase inhibitor antidepressants were observed.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The authors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive disorder. METHOD: Following a 1-week placebo lead-in, 177 adult outpatients with major depressive disorder were randomly assigned to receive transdermal selegiline (20 mg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1176/appi.ajp.159.11.1869

データ提供：米国国立医学図書館（NLM）

Transdermal Selegiline: A Novel Treatment for Major Depression

The desert of depression can be a lonely and isolating place. This study explores the efficacy and safety of transdermal selegiline, a novel treatment for major depressive disorder. Selegiline, a monoamine oxidase inhibitor, has traditionally been administered orally, but this research investigates its potential when delivered transdermally.

Transdermal Selegiline: A Promising New Approach

The study found that transdermal selegiline was an effective and well-tolerated treatment for major depressive disorder in adult outpatients. The transdermal delivery system appears to offer an alternative to traditional oral administration, potentially minimizing the risk of common side effects associated with oral monoamine oxidase inhibitors. The study suggests that transdermal selegiline may be a valuable addition to the treatment options available for depression.

Navigating the Desert of Depression

This research provides hope for those struggling with depression. It's a testament to the ongoing search for new and innovative treatments that can help individuals find their way out of the desert of depression. It's important to remember that depression is treatable, and there are resources available to help individuals find the support they need.

Dr.Camel's Conclusion

This research is like a refreshing spring in the desert of depression. It offers a new perspective on the treatment of this debilitating condition, providing hope for a brighter future.

Date :
  1. Date Completed 2002-12-04
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

12411221

DOI: Digital Object Identifier

10.1176/appi.ajp.159.11.1869

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.